Nivolumab biosimilar(NeuClone/Serum Institute of India)

纳武利尤单抗生物类似药（NeuClone/Serum Institute of India）

Report date: 2025/02/18 11:33:17

Base Information

Drug NameNivolumab biosimilar(NeuClone/Serum Institute of India)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionProgrammed cell death protein 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNeucloneSerum Institute Of India Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNeucloneSerum Institute Of India Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A